セキ　マサフミ   SEK Masafumi   関　雅文    所属   埼玉医科大学  医学部 国際医療センター　感染症科・感染制御科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure.
掲載誌名	正式名：Clinical pharmacology : advances and applications ISSNコード：11791438
巻・号・頁	5,161-6頁
著者・共著者	Kaori Yabuno,Masafumi Seki,Koji Miyawaki,Yoshihiro Miwa,Kazunori Tomono
発行年月	2013
概要	BACKGROUND: The recommended daptomycin dosage is 4 or 6 mg/kg/day for the treatment of complicated skin and soft tissue infections or for Staphylococcus aureus bacteremia, endocarditis, and osteomyelitis. Every other day administration is usually recommended for patients with mild to moderate renal impairment. Higher doses (>6 mg/kg/day) have been explored as a possible alternative. Daptomycin is considered a safe anti-methicillin-resistant S. aureus (MRSA) drug, although renal dysfunction may be worsened. In this paper we report on three patients with chronic renal failure who received a higher dose of daptomycin daily for successful treatment for MRSA bacteremia, MRSA osteomyelitis, and methicillin-resistant S. epidermidis (MRSE) endocarditis. RESULTS: Previous administration of other drugs, including vancomycin, teicoplanin, and linezolid, had failed. In spite of daily treatment with daptomycin instead of the recommended alternate day regimen, adverse effects, such as elevation of creatinine and creatine phosphokinase, did not occur. CONCLUSION: These experiences suggest that administration of high-dose/short-interval daptomycin can be efficient and safe even in the setting of r
DOI	10.2147/CPAA.S53681
PMID	24235850